​

Context Therapeutics (CNTX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

CNTX Stock Forecast

Context Therapeutics (CNTX) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $5.25, with a high of $6.00 and a low of $4.50. This represents a 348.72% increase from the last price of $1.17.

$1 $2 $3 $4 $5 $6 High: $6 Avg: $5.25 Low: $4.5 Last Closed Price: $1.17

CNTX Stock Rating

Context Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

CNTX Price Target Upside V Benchmarks

TypeNameUpside
StockContext Therapeutics348.72%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.17$1.17$1.17
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2543---7
Sep, 2542---6
Aug, 2542---6
Jul, 2542---6
Jun, 2532---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 08, 2024Emily BodnarH.C. Wainwright$6.00$2.34156.41%412.82%
May 16, 2024Joseph CatanzaroPiper Sandler$4.50$1.69166.27%284.62%
May 09, 2024Emily BodnarH.C. Wainwright$5.00$1.81176.24%327.35%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 02, 2025Cantor FitzgeraldOverweightinitialise
Sep 17, 2025GuggenheimBuyinitialise
Apr 21, 2025William BlairOutperforminitialise
Sep 24, 2024H.C. WainwrightBuyBuyhold
Sep 16, 2024Piper SandlerOverweightOverweighthold
Aug 08, 2024H.C. WainwrightBuyBuyhold
May 16, 2024Piper SandlerOverweightinitialise
May 09, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.50$-0.46----
Avg Forecast$-1.44$-0.58$-0.44$-0.53$-0.62$-0.69
High Forecast$-1.41$-0.56$-0.35$-0.27$-0.29$-0.69
Low Forecast$-1.46$-0.60$-0.50$-0.97$-1.05$-0.69
Surprise %4.17%-20.69%----

Revenue Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$2.00M-$15.11M
High Forecast---$2.00M-$15.11M
Low Forecast---$2.00M-$15.11M
Surprise %------

Net Income Forecast

$-30M $-24M $-18M $-12M $-6M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-23.96M$-26.73M----
Avg Forecast$-22.96M$-9.26M$-6.85M$-9.90M$-10.70M$-11.02M
High Forecast$-22.56M$-8.90M$-5.66M$-4.31M$-4.63M$-11.02M
Low Forecast$-23.37M$-9.62M$-8.05M$-15.49M$-16.76M$-11.02M
Surprise %4.36%188.60%----

CNTX Forecast FAQ

Is Context Therapeutics stock a buy?

Context Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Context Therapeutics is a favorable investment for most analysts.

What is Context Therapeutics's price target?

Context Therapeutics's price target, set by 5 Wall Street analysts, averages $5.25 over the next 12 months. The price target range spans from $4.5 at the low end to $6 at the high end, suggesting a potential 348.72% change from the previous closing price of $1.17.

How does Context Therapeutics stock forecast compare to its benchmarks?

Context Therapeutics's stock forecast shows a 348.72% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Context Therapeutics over the past three months?

  • October 2025: 57.14% Strong Buy, 42.86% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Context Therapeutics’s EPS forecast?

Context Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.44, marking a -4.35% decrease from the reported $-0.46 in 2024. Estimates for the following years are $-0.53 in 2026, $-0.62 in 2027, and $-0.69 in 2028.

What is Context Therapeutics’s revenue forecast?

Context Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $2M, followed by $0 for 2027, and $15.11M for 2028.

What is Context Therapeutics’s net income forecast?

Context Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-6.852M, representing a -74.36% decrease from the reported $-26.725M in 2024. Projections indicate $-9.899M in 2026, $-10.697M in 2027, and $-11.017M in 2028.